ClinicalTrials.gg
CompletedNCT01706198Updated Jan 24, 2019Results posted

An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma

A Phase 3 interventional study of fluticasone furoate + vilanterol and inhaled corticosteroid with or without a long acting beta2-agonist in Asthma, sponsored by GlaxoSmithKline. Completed at 180 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-24.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,233
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
Largest of 40
4,233 · median 102
Started
2012
with 1 other
Phase 3
14 of 40
none open now
Registered
25th of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one has the largest enrollment, is one of 2 that started in 2012, is one of 14 in phase 3, and was the 25th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) or 200mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) ) delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with the existing asthma maintenance therapy over twelve months in subjects diagnosed with asthma. This is a Phase III multi-centre, randomised open label study. Subjects who meet the eligibility criteria are randomised and will enter a 12 month treatment period.

Read the detailed description

This is a Phase III multi-centre, randomised open label study performed in subjects followed in primary care who have a diagnosis of and receive regular treatment for asthma in a localised geographical region of the UK

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • respiratory
  • adult
  • asthma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for enrolment in the study must meet all of the following criteria:

  1. : Subjects must be able to provide informed consent, have their consent signed and dated.
  2. Type of subject: Subjects with documented GP diagnosis of asthma as their primary respiratory disease.
  3. Current Anti-Asthma Therapy: All subjects must be prescribed maintenance therapy and receiving ICS with or without LABA (either a fixed combination or via separate inhalers), and for at least 4 weeks prior to Visit 2.

    • Other background asthma medication such as anti-leukotrienes are permitted
  4. All subjects on ICS monotherapy or ICS/LABA combination (this can be a fixed dose combination or an ICS alone or LABA alone in separate inhalers) must have had symptoms in the past week prior to Visit 2. Symptoms are defined by daytime symptoms more than twice per week, use of short-acting beta2-agonist bronchodilator more than twice per week, any limitation of activities, or any nocturnal symptoms/awakening. (The symptoms are based on subject's recall and are consistent with the GINA and in principal with the BTS/SIGN guidelines).
  5. Subject questionnaires: Subjects must be able to complete the electronic subject questionnaires as well as those questionnaires that are completed by phone or provide a proxy e.g. a partner/relative/a friend who can do so on their behalf
  6. Gender and Age: Male or female subjects aged ≥18 years of age at Visit 1. A female is eligible to enter and participate in the study if she is of:

    • Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms. However in questionable cases, a blood sample with FSH > 40MIU/ml and estradiol \<40pg/ml (\<147 pmol/L) is confirmatory.

OR Child bearing potential has a negative urine pregnancy test at Visit 2, and agrees to one of the highly effective and acceptable methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study - Visit 2 to the end of the study).

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria must not be enrolled in the study:

  1. Recent history of Life-threatening asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 6 months.
  2. Respiratory Disease: A subject must not have current evidence or GP diagnosis of chronic obstructive pulmonary disease.
  3. Other diseases/abnormalities: Subjects with historical or current evidence of uncontrolled or disease. Significant is defined as any disease that, in the opinion of the GP/ Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  4. Drug/food allergy: Subjects with a history of to any of the study medications (e.g., beta2-agonists, ) or components of the inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the GP/ Investigator, contraindicates the subject's participation will also be excluded.
  5. Medications: A subject must not have used any investigational drug within 30 days prior to Visit 2 or within five half-lives (t½) of the prior investigational study (whichever is longer of the two), (if unsure discuss with the medical monitor prior to screening)
  6. Chronic user of systemic corticosteroids: A subject who, in the opinion of the GP/Investigator, is considered to be a chronic user of systemic corticosteroids for respiratory or other indications (if unsure discuss with the medical monitor prior to screening)
  7. Subjects who are using LABA without an ICS as asthma maintenance therapy.
  8. Subjects who plan to move away from the geographical area where the study is being conducted during the study period and/or if subjects have not consented to their medical records being part of the electronic medical records database that is operational in the Salford area.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4,233 participants (actual)

Study arms

  • Experimental
    FF/VI

    fluticasone furoate (FF) + vilanterol (VI) once daily via a Novel Dry Powder Inhaler

    Drug: fluticasone furoate + vilanterol · Drug: inhaled corticosteroid with or without a long acting beta2-agonist

  • Active comparator
    ICS or ICS/LABA maintenance therapy

    inhaled corticosteroid (ICS) alone or in combination with a long acting beta2-agonist (LABA)

    Drug: inhaled corticosteroid with or without a long acting beta2-agonist

Interventions

  • Drugfluticasone furoate + vilanterol

    Drug pages: Fluticasone furoate · Vilanterol

    once daily via a Novel Dry Powder Inhaler

  • Druginhaled corticosteroid with or without a long acting beta2-agonist

    ICS alone or in combination with a long acting bronchodilator

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Have Either an Asthma Control Test (ACT) Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Week 24.

    The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The primary efficacy analysis (PEA) Population is defined as all Intent-to-Treat (ITT) participants (that is, all participants who were randomized and received at least one prescription of study medication) who have an ACT total score of \<20 at Baseline (Day 0). The percentage of responders that is participants with an ACT total score \>=20 or an increase from Baseline of \>=3 has been presented

    Time frame: Baseline (Day 0) and Week 24

Secondary outcomes

  1. Percentage of Participants Who Have Either an ACT Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 40 and 52.

    The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. ITT Population comprised of all participants who were randomized and received at least one prescription of study medication. The percentage of responders that is participants with an ACT total score \>=20 or an increase from Baseline of \>=3 has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline (Day 0) and Weeks 12, 40 and 52

  2. Percentage of Participants With Asthma Control (ACT Total Score >=20) at Weeks 12, 24, 40 and 52.

    The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The percentage of participants with an ACT total score \>=20 has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Weeks 12, 24, 40 and 52

  3. Percentage of Participants Who Have an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 24, 40 and 52.

    The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The percentage of participants with an increase in ACT total score \>=3 from Baseline has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline (Day 0) and Weeks 12, 24, 40 and 52

  4. Mean Change From Baseline in ACT Total Score at Weeks 12, 24, 40 and 52.

    The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. Baseline value is the value at Visit 2 (Day 0) assessment. Change from Baseline is the value at post-dose visit minus Baseline. The least square mean change in ACT scores has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Baseline (Day 0) and Weeks 12, 24, 40 and 52

  5. Percentage of Participants in Each ACT Total Score Category (>=20, 16 to 19, <=15) at Weeks 12, 24, 40 and 52.

    The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The percentage of participants under each ACT total score category that is \>=20, 16 to 19 and \<=15 has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

    Time frame: Weeks 12, 24, 40 and 52

  6. Annual Rate of Asthma-related Secondary Care Contacts

    All contacts are defined as any encounter the participant may have with a doctor, nurse or other healthcare professionals working as part of the National Health Service (NHS) as identified in the electronic medical records (EMR). Contacts were defined to be asthma-related if the most prominent signs and symptoms that the participant presented were a direct result of the participant's asthma. An asthma-related secondary care contact is defined as an inpatient admission or a specialist outpatient visit or an accident and emergency (A\&E) contact. A participant with an A\&E contact and subsequent inpatient admission was considered to have had two healthcare contacts. The least square mean annual rate of all asthma-related secondary care contacts along with 95% confidence interval has been presented.

    Time frame: Up to Week 52

  7. Annual Rate of Asthma-related Primary Care Contacts

    All contacts are defined as any encounter the participant may have with a doctor, nurse or other healthcare professionals working as part of the NHS as identified in the EMR. Contacts were defined to be asthma-related if the most prominent signs and symptoms that the participant presented were a direct result of the participant's asthma. Asthma-related primary care contacts is defined as the sum of primary care contacts on a given calendar date with either a nurse, General Practitioner or other healthcare professional that can be considered as asthma-related as per Read codes. The least square mean annual rate of all asthma-related primary care contacts along with 95% confidence interval has been presented.

    Time frame: Up to Week 52

  8. Number of Participants With Time to First Asthma-related Primary Care Contact

    Asthma-related primary care contact is defined as the sum of primary care contacts on a given calendar date with either a nurse, General Practitioner or other healthcare professional that can be considered as asthma-related as per Read codes. Time to first asthma-related primary care contact was measured from the date of randomization (that is, study treatment start date) to the date of first asthma-related primary care contact, or study treatment stop date for participants who completed the study without any asthma-related primary care contacts (censored). Analyses of time to first asthma-related primary care contact was censored at Day 364. The number of participants at risk at Weeks 0, 13, 26, 39 and 52 has been presented. Kaplan Meier method of analysis was used. Study related primary care contacts (that is, contacts scheduled solely due to the participant taking part in clinical trial) were excluded from this analysis.

    Time frame: Up to Week 52

  9. Annual Rate of All On-treatment Secondary Care Contacts

    A secondary care contact is defined as an inpatient admission or a specialist outpatient visit or an A\&E contact. A participant with an A\&E contact and subsequent inpatient admission was considered to have had two healthcare contacts. The inpatient admissions recorded at two hospitals on the same day, were counted as a single (inpatient admission) secondary care contact. In the situation where inpatient admission periods overlapped (example, a new inpatient admission was recorded within the dates of an existing inpatient admission period), it was counted as a single (inpatient admission) healthcare contact with start date defined as the earliest inpatient admission date for either of the overlapping admissions and end date defined as the latest discharge date for either of the overlapping admissions. The least square mean annual rate of all on-treatment secondary care contacts along with 95% confidence interval has been summarized.

    Time frame: Up to Week 52

  10. Annual Rate of All On-treatment Primary Care Contacts

    All contacts are defined as any encounter the participant may have with a doctor, nurse or other healthcare professionals working as part of the NHS as identified in the EMR. Total primary care contacts is defined as the sum of primary care contacts on a given calendar date with either a nurse, General Practitioner or other healthcare professional. The least square mean annual rate of all on-treatment primary care contacts along with 95% confidence interval has been presented.

    Time frame: Up to Week 52

  11. Number of Participants With Time to First Primary Care Contact

    Time to first primary care contact is measured from the date of randomization (that is, study treatment start date) to the date of first primary care contact, or study treatment stop date for participants who completed the study without any primary care contacts (censored). Analyses of time to first primary care contact will be censored at Day 364. The number of participants at risk at Weeks 0, 13, 26, 39 and 52 has been presented. Kaplan Meier method of analysis was used. Study related primary care contacts (that is, contacts scheduled solely due to the participant taking part in clinical trial) were excluded from this analysis.

    Time frame: Up to Week 52

  12. Mean Annual Rate of Severe Asthma Exacerbations

    A severe asthma exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) or antibiotics, and inpatient hospitalization, or emergency department visit due to asthma that required systemic corticosteroids or antibiotics. Least square mean for annual rate of severe asthma exacerbation along with 95% confidence interval has been presented.

    Time frame: Up to Week 52

  13. Time to First Severe Asthma Exacerbation.

    A severe asthma exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) or antibiotics, and inpatient hospitalization, or emergency department visit due to asthma that required systemic corticosteroids or antibiotics. The date of a severe asthma exacerbation was defined as the exacerbation onset date. Participants who completed the study without a severe asthma exacerbation were censored. Time to first severe asthma exacerbation was measured from the date of randomization (that is, study treatment start date) to the onset date of first severe asthma exacerbation, or study treatment stop date for participants who completed the study without any severe asthma exacerbations (censored). Analyses of time to first severe asthma exacerbation was censored at Day 364. The number of participants with severe asthma exacerbation has been presented.

    Time frame: Up to Week 52

  14. Mean Number of Salbutamol Inhalers Prescribed for Each Participant Over the 12 Month Treatment Period.

    Salbutamol was prescribed as a rescue medication to be used as and when necessary throughout the study. The number of salbutamol inhalers used by each participant during the study was calculated based on the total number of inhalers (adjusted to an equivalence of 200 metered actuations) prescribed. Number of salbutamol inhalers prescribed during the study was derived taking the participants time on study medication into account so it corresponds to 12 months on treatment. The least square mean number of salbutamol inhalers prescribed per participant during the study has been presented. Only participants exposed to study drug for at least 30 days were included in the analysis.

    Time frame: Up to 12 months

  15. Time to Modification of Initial Therapy

    Initial therapy is defined as the treatment that the participant was prescribed at randomization. Modification of initial therapy included any change in brand, dose or frequency of inhaler, that is, stepping up in class, dose or frequency, stepping down in class, dose or frequency, switching to another brand of inhaler, switching treatment arm or withdrawal from the study. Time to modification of initial therapy was measured from the date of randomization (that is, exposure start date) to the date of modification of initial therapy or date of treatment termination for participants who completed the study without modifiying initial therapy (censored). The number of participants with modification of initial therapy has been presented.

    Time frame: Up to Week 52

  16. Percentage of Participants Who Have an Increase From Baseline of >=0.5 in Standardized Asthma Quality of Life Questionnaire [AQLQ(S)] Total Score at Week 52.

    The AQLQ(S) contained 32 items under the following four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items) and environmental stimuli (4 items). The response format consisted of a seven-point scale where a value of 1 indicated "total impairment" and a value of 7 indicated "no impairment". The total AQLQ(S) score is the mean of all 32 items in the questionnaire and each individual domain score was calculated as the mean of the items within that domain. Hence, the total and domain scores were each defined on a range from 1 to 7 with higher scores indicating a higher quality of life. Baseline value is the value at Day 0 assessment. Change from Baseline is post dose visit value minus Baseline. The percentage of responders that is, participants with an increase from Baseline of \>=0.5 in AQLQ(S) total score has been presented. Only those participants available at the specified time point was analyzed.

    Time frame: Baseline (Day 0) and Week 52

  17. Percentage of Participants Who Have an Increase From Baseline of >=0.5 in AQLQ(S) Environmental Stimuli Domain Score at Week 52.

    The AQLQ(S) contained 32 items under the following four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items) and environmental stimuli (4 items). The response format consisted of a seven-point scale where a value of 1 indicated "total impairment" and a value of 7 indicated "no impairment". The total environmental stimuli domain score was calculated as the mean of the items within the environmental stimuli domain. Hence, the environmental stimuli domain scores were each defined on a range from 1 to 7 with higher scores indicating a higher quality of life. Baseline value is the value at Day 0 assessment. Change from Baseline is post dose visit value minus Baseline. The percentage of responders that is, participants with an increase from Baseline of \>=0.5 in AQLQ(S) environmental stimuli domain score has been presented. Only those participants available at the specified time point was analyzed.

    Time frame: Baseline (Day 0) and Week 52

  18. Percentage of Participants With Serious Adverse Event (SAE) of Pneumonia

    A serious advent event (SAE) of pneumonia was defined as any SAE in the adverse event special interest (AESI) group of "pneumonia". The incidence of the SAEs of pneumonia for each treatment group is defined as the percentage of participants in that group who have experienced at least one SAE of pneumonia from start date of study treatment to the stop date of exposure + 28 days or date of study discontinuation, whichever is earliest. The percentage of participants with SAE of pneumonia has been presented.

    Time frame: Up to Week 52

  19. Time to First SAE of Pneumonia

    An SAE of pneumonia was defined as any SAE in the AESI group of "pneumonia". The date of an event for an SAE of pneumonia was the AE onset date. Participants who do not have an SAE of pneumonia during the first 364 days of the treatment period (start date of exposure to min \[end date of exposure + 28 days, date of study discontinuation, start date of exposure + 363\]) were censored. Time to first SAE of pneumonia was measured from the date of randomization (that is, study treatment start date) to the onset date of first SAE of pneumonia. The number of participants with first on-treatment SAE of pneumonia has been presented.

    Time frame: Up to Week 52

  20. Number of Participants With Fatal SAEs of Pneumonia

    All SAEs included in the AESI group of "pneumonia" were considered as an SAE of pneumonia. Fatal SAEs of pneumonia are SAEs that led to death of participants. The number of participants with fatal SAEs of pneumonia has been presented.

    Time frame: Up to Week 52

  21. Number of Participants With SAEs

    An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events which may require medical or surgical intervention for example, invasive or malignant cancers; all events of possible drug-induced liver injury with hyperbilirubinemia. The number of participants with on-treatment SAEs has been summarized.

    Time frame: Up to Week 52

  22. Number of Participants With Adverse Drug Reactions (ADRs)

    An ADR is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, for which there is a reasonable possibility that the untoward occurrence is causally related to the medicinal product. ADRs are a subset of AEs for a given medicinal product.

    Time frame: Up to Week 52

07

Results

Posted Jan 24, 2019

Participant flow

This was a multi-center, randomized, open label study to evaluate the effectiveness of fluticasone furoate (FF)/vilanterol (VI) Inhalation Powder (FF 100 micrograms \[mcg\]/VI 25 mcg or FF 200 mcg/VI 25 mcg) compared with usual asthma maintenance therapy in participants with asthma in a localized geographical region of United Kingdom.

Participant flow — Overall Study
MilestoneUsual CareFF/VI
Started21192114
Completed19461920
Not completed173194
Withdrew: Adverse event1215
Withdrew: Protocol violation75
Withdrew: Other: subject reached stopping criteria1113
Withdrew: Lost to follow-up9793
Withdrew: Physician decision2337
Withdrew: Withdrawal by subject2331

Outcome measures

PrimaryPercentage of Participants Who Have Either an Asthma Control Test (ACT) Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Week 24.

The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The primary efficacy analysis (PEA) Population is defined as all Intent-to-Treat (ITT) participants (that is, all participants who were randomized and received at least one prescription of study medication) who have an ACT total score of \<20 at Baseline (Day 0). The percentage of responders that is participants with an ACT total score \>=20 or an increase from Baseline of \>=3 has been presented

Time frame:
Baseline (Day 0) and Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Have Either an Asthma Control Test (ACT) Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Week 24.
Percentage of participantsUsual CareFF/VI
Percentage of Participants Who Have Either an Asthma Control Test (ACT) Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Week 24.5671
Statistical analysis
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (The analysis method was logistic regression adjusted for randomized treatment, asthma maintenance therapy (AMT) at Baseline per randomization stratification, Baseline ACT total score, Baseline ACT total score squared, gender and age.) · Adjusted odds ratio: 2.00 · 95% CI 1.70 to 2.34Adjusted odds ratio comparing FF/VI with Usual Care has been presented.
SecondaryPercentage of Participants Who Have Either an ACT Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 40 and 52.

The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. ITT Population comprised of all participants who were randomized and received at least one prescription of study medication. The percentage of responders that is participants with an ACT total score \>=20 or an increase from Baseline of \>=3 has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline (Day 0) and Weeks 12, 40 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Have Either an ACT Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 40 and 52.
Percentage of participantsUsual CareFF/VI
Week 12, n=2032, 20096275
Week 40, n=1938, 19046071
Week 52, n=1922, 18965870
Statistical analysis
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (Logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, Baseline ACT total score squared, gender and age.) · Adjusted odds ratio: 1.92 · 95% CI 1.67 to 2.20Adjusted odds ratio comparing FF/VI with Usual Care for Week 12 has been presented.
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (Logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, Baseline ACT total score squared, gender and age.) · Adjusted odds ratio: 1.66 · 95% CI 1.45 to 1.91Adjusted odds ratio comparing FF/VI with Usual Care for Week 40 has been presented.
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (Logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, Baseline ACT total score squared, gender and age.) · Adjusted odds ratio: 1.76 · 95% CI 1.54 to 2.02Adjusted odds ratio comparing FF/VI with Usual Care for Week 52 has been presented.
SecondaryPercentage of Participants With Asthma Control (ACT Total Score >=20) at Weeks 12, 24, 40 and 52.

The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The percentage of participants with an ACT total score \>=20 has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Weeks 12, 24, 40 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Asthma Control (ACT Total Score >=20) at Weeks 12, 24, 40 and 52.
Percentage of participantsUsual CareFF/VI
Week 12, n=2032, 20094661
Week 24, n=1957, 19364660
Week 40, n=1938, 19044558
Week 52, n=1922, 18964458
Statistical analysis
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.) · Adjusted odds ratio: 2.09 · 95% CI 1.82 to 2.40Adjusted odds ratio comparing FF/VI with Usual Care at Week 12 has been presented.
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.) · Adjusted odds ratio: 1.96 · 95% CI 1.70 to 2.25Adjusted odds ratio comparing FF/VI with Usual Care at Week 24 has been presented.
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.) · Adjusted odds ratio: 1.79 · 95% CI 1.56 to 2.06Adjusted odds ratio comparing FF/VI with Usual Care at Week 40 has been presented.
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.) · Adjusted odds ratio: 1.95 · 95% CI 1.69 to 2.24Adjusted odds ratio comparing FF/VI with Usual Care at Week 52 has been presented.
SecondaryPercentage of Participants Who Have an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 24, 40 and 52.

The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The percentage of participants with an increase in ACT total score \>=3 from Baseline has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline (Day 0) and Weeks 12, 24, 40 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Have an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 24, 40 and 52.
Percentage of participantsUsual CareFF/VI
Week 12, n=2032, 20093955
Week 24, n=1957, 19364054
Week 40, n=1938, 19044253
Week 52, n=1922, 18963750
Statistical analysis
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.) · Adjusted odds ratio: 2.28 · 95% CI 1.98 to 2.62Adjusted odds ratio comparing FF/VI with Usual Care at Week 12 has been presented.
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.) · Adjusted odds ratio: 2.09 · 95% CI 1.81 to 2.41Adjusted odds ratio comparing FF/VI with Usual Care at Week 24 has been presented.
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.) · Adjusted odds ratio: 1.76 · 95% CI 1.53 to 2.02Adjusted odds ratio comparing FF/VI with Usual Care at Week 40 has been presented.
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.) · Adjusted odds ratio: 1.91 · 95% CI 1.66 to 2.21Adjusted odds ratio comparing FF/VI with Usual Care at Week 52 has been presented.
SecondaryMean Change From Baseline in ACT Total Score at Weeks 12, 24, 40 and 52.

The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. Baseline value is the value at Visit 2 (Day 0) assessment. Change from Baseline is the value at post-dose visit minus Baseline. The least square mean change in ACT scores has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Baseline (Day 0) and Weeks 12, 24, 40 and 52
Reported as:
Least squares mean · Scores on ACT scale
Mean Change From Baseline in ACT Total Score at Weeks 12, 24, 40 and 52.
Scores on ACT scaleUsual CareFF/VI
Week 12, n=2032, 20091.77 ± 0.0873.31 ± 0.087
Week 24, n=1957, 19361.70 ± 0.0933.20 ± 0.094
Week 40, n=1938, 19041.63 ± 0.0963.00 ± 0.097
Week 52, n=1922, 18961.49 ± 0.0942.99 ± 0.095
Statistical analysis
  • Usual Care vs FF/VI · Mixed Model Repeated Measures (MMRM) · p = <0.001 (MMRM adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, randomized treatment-by-Baseline ACT total score interaction, gender, age, visit and randomized treatment by visit interaction.) · Mean difference (net): 1.54 · 95% CI 1.30 to 1.77Treatment difference of FF/VI versus Usual Care at Week 12 has been presented.
  • Usual Care vs FF/VI · MMRM · p = <0.001 (MMRM adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, randomized treatment-by-Baseline ACT total score interaction, gender, age, visit and randomized treatment by visit interaction.) · Mean difference (net): 1.50 · 95% CI 1.25 to 1.76Treatment difference of FF/VI versus Usual Care at Week 24 has been presented.
  • Usual Care vs FF/VI · MMRM · p = <0.001 (MMRM adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, randomized treatment-by-Baseline ACT total score interaction, gender, age, visit and randomized treatment by visit interaction.) · Mean difference (net): 1.37 · 95% CI 1.11 to 1.63Treatment difference of FF/VI versus Usual Care at Week 40 has been presented.
  • Usual Care vs FF/VI · MMRM · p = <0.001 (MMRM adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, randomized treatment-by-Baseline ACT total score interaction, gender, age, visit and randomized treatment by visit interaction.) · Mean difference (net): 1.50 · 95% CI 1.24 to 1.76Treatment difference of FF/VI versus Usual Care at Week 52 has been presented.
SecondaryPercentage of Participants in Each ACT Total Score Category (>=20, 16 to 19, <=15) at Weeks 12, 24, 40 and 52.

The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The percentage of participants under each ACT total score category that is \>=20, 16 to 19 and \<=15 has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).

Time frame:
Weeks 12, 24, 40 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants in Each ACT Total Score Category (>=20, 16 to 19, <=15) at Weeks 12, 24, 40 and 52.
Percentage of participantsUsual CareFF/VI
>=20, Week 12, n=2032, 20094661
16 to 19, Week 12, n=2032, 20092620
<=15, Week 12, n=2032, 20092818
>=20, Week 24, n=1957, 19364660
16 to 19, Week 24, n=1957, 19362520
<=15, Week 24, n=1957, 19362920
>=20, Week 40, n=1938, 19044558
16 to 19, Week 40, n=1938, 19042421
<=15, Week 40, n=1938, 19043121
>=20, Week 52, n=1922, 18964458
16 to 19, Week 52, n=1922, 18962620
<=15, Week 52, n=1922, 18963021
SecondaryAnnual Rate of Asthma-related Secondary Care Contacts

All contacts are defined as any encounter the participant may have with a doctor, nurse or other healthcare professionals working as part of the National Health Service (NHS) as identified in the electronic medical records (EMR). Contacts were defined to be asthma-related if the most prominent signs and symptoms that the participant presented were a direct result of the participant's asthma. An asthma-related secondary care contact is defined as an inpatient admission or a specialist outpatient visit or an accident and emergency (A\&E) contact. A participant with an A\&E contact and subsequent inpatient admission was considered to have had two healthcare contacts. The least square mean annual rate of all asthma-related secondary care contacts along with 95% confidence interval has been presented.

Time frame:
Up to Week 52
Reported as:
Least squares mean · Contacts per participant per year
Annual Rate of Asthma-related Secondary Care Contacts
Contacts per participant per yearUsual CareFF/VI
Annual Rate of Asthma-related Secondary Care Contacts0.30 (0.25 to 0.34)0.30 (0.26 to 0.36)
Statistical analysis
  • Usual Care vs FF/VI · Generalized Linear Model (GLM) · p = 0.786 (GLM assuming negative binomial distribution (NBD) adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age) · Ratio: 1.03 · 95% CI 0.83 to 1.28Ratio comparing FF/VI with Usual Care has been presented.
SecondaryAnnual Rate of Asthma-related Primary Care Contacts

All contacts are defined as any encounter the participant may have with a doctor, nurse or other healthcare professionals working as part of the NHS as identified in the EMR. Contacts were defined to be asthma-related if the most prominent signs and symptoms that the participant presented were a direct result of the participant's asthma. Asthma-related primary care contacts is defined as the sum of primary care contacts on a given calendar date with either a nurse, General Practitioner or other healthcare professional that can be considered as asthma-related as per Read codes. The least square mean annual rate of all asthma-related primary care contacts along with 95% confidence interval has been presented.

Time frame:
Up to Week 52
Reported as:
Least squares mean · Contacts per participant per year
Annual Rate of Asthma-related Primary Care Contacts
Contacts per participant per yearUsual CareFF/VI
Annual Rate of Asthma-related Primary Care Contacts1.42 (1.36 to 1.47)1.45 (1.39 to 1.51)
Statistical analysis
  • Usual Care vs FF/VI · Generalized Linear Model (GLM) · p = 0.461 (GLM assuming NBD adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age) · Ratio: 1.02 · 95% CI 0.97 to 1.08Ratio comparing FF/VI with Usual Care has been presented.
SecondaryNumber of Participants With Time to First Asthma-related Primary Care Contact

Asthma-related primary care contact is defined as the sum of primary care contacts on a given calendar date with either a nurse, General Practitioner or other healthcare professional that can be considered as asthma-related as per Read codes. Time to first asthma-related primary care contact was measured from the date of randomization (that is, study treatment start date) to the date of first asthma-related primary care contact, or study treatment stop date for participants who completed the study without any asthma-related primary care contacts (censored). Analyses of time to first asthma-related primary care contact was censored at Day 364. The number of participants at risk at Weeks 0, 13, 26, 39 and 52 has been presented. Kaplan Meier method of analysis was used. Study related primary care contacts (that is, contacts scheduled solely due to the participant taking part in clinical trial) were excluded from this analysis.

Time frame:
Up to Week 52
Reported as:
Number · Participants
Number of Participants With Time to First Asthma-related Primary Care Contact
ParticipantsUsual CareFF/VI
Week 021192114
Week 1316211599
Week 2612081214
Week 39907932
Week 52479488
SecondaryAnnual Rate of All On-treatment Secondary Care Contacts

A secondary care contact is defined as an inpatient admission or a specialist outpatient visit or an A\&E contact. A participant with an A\&E contact and subsequent inpatient admission was considered to have had two healthcare contacts. The inpatient admissions recorded at two hospitals on the same day, were counted as a single (inpatient admission) secondary care contact. In the situation where inpatient admission periods overlapped (example, a new inpatient admission was recorded within the dates of an existing inpatient admission period), it was counted as a single (inpatient admission) healthcare contact with start date defined as the earliest inpatient admission date for either of the overlapping admissions and end date defined as the latest discharge date for either of the overlapping admissions. The least square mean annual rate of all on-treatment secondary care contacts along with 95% confidence interval has been summarized.

Time frame:
Up to Week 52
Reported as:
Least squares mean · Contacts per participant per year
Annual Rate of All On-treatment Secondary Care Contacts
Contacts per participant per yearUsual CareFF/VI
Annual Rate of All On-treatment Secondary Care Contacts5.23 (4.91 to 5.57)5.17 (4.86 to 5.51)
Statistical analysis
  • Usual Care vs FF/VI · Generalized Linear Model (GLM) · p = 0.822 (GLM assuming NBD adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age) · Ratio: 0.99 · 95% CI 0.91 to 1.08Ratio comparing FF/VI with Usual Care has been presented.
SecondaryAnnual Rate of All On-treatment Primary Care Contacts

All contacts are defined as any encounter the participant may have with a doctor, nurse or other healthcare professionals working as part of the NHS as identified in the EMR. Total primary care contacts is defined as the sum of primary care contacts on a given calendar date with either a nurse, General Practitioner or other healthcare professional. The least square mean annual rate of all on-treatment primary care contacts along with 95% confidence interval has been presented.

Time frame:
Up to Week 52
Reported as:
Least squares mean · Contacts per participant per year
Annual Rate of All On-treatment Primary Care Contacts
Contacts per participant per yearUsual CareFF/VI
Annual Rate of All On-treatment Primary Care Contacts10.61 (10.26 to 10.98)11.64 (11.25 to 12.04)
Statistical analysis
  • Usual Care vs FF/VI · Generalized Linear Model (GLM) · p = <0.001 (GLM assuming NBD adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age) · Ratio: 1.10 · 95% CI 1.05 to 1.15Ratio comparing FF/VI with Usual Care has been presented.
SecondaryNumber of Participants With Time to First Primary Care Contact

Time to first primary care contact is measured from the date of randomization (that is, study treatment start date) to the date of first primary care contact, or study treatment stop date for participants who completed the study without any primary care contacts (censored). Analyses of time to first primary care contact will be censored at Day 364. The number of participants at risk at Weeks 0, 13, 26, 39 and 52 has been presented. Kaplan Meier method of analysis was used. Study related primary care contacts (that is, contacts scheduled solely due to the participant taking part in clinical trial) were excluded from this analysis.

Time frame:
Up to Week 52
Reported as:
Number · Participants
Number of Participants With Time to First Primary Care Contact
ParticipantsUsual CareFF/VI
Week 021192114
Week 13513483
Week 26245242
Week 39160178
Week 527996
SecondaryMean Annual Rate of Severe Asthma Exacerbations

A severe asthma exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) or antibiotics, and inpatient hospitalization, or emergency department visit due to asthma that required systemic corticosteroids or antibiotics. Least square mean for annual rate of severe asthma exacerbation along with 95% confidence interval has been presented.

Time frame:
Up to Week 52
Reported as:
Least squares mean · Exacerbations per participant per year
Mean Annual Rate of Severe Asthma Exacerbations
Exacerbations per participant per yearUsual CareFF/VI
Mean Annual Rate of Severe Asthma Exacerbations0.41 (0.38 to 0.44)0.40 (0.37 to 0.43)
Statistical analysis
  • Usual Care vs FF/VI · Generalized Linear Model (GLM) · p = 0.697 (GLM assuming NBD adjusted for randomized treatment; asthma maintenance therapy and ACT total score at Baseline per randomization stratification; number of severe asthma exacerbations in previous year prior to randomization categorized; gender \& age) · Ratio: 0.98 · 95% CI 0.88 to 1.09Ratio comparing FF/VI with Usual Care has been presented.
SecondaryTime to First Severe Asthma Exacerbation.

A severe asthma exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) or antibiotics, and inpatient hospitalization, or emergency department visit due to asthma that required systemic corticosteroids or antibiotics. The date of a severe asthma exacerbation was defined as the exacerbation onset date. Participants who completed the study without a severe asthma exacerbation were censored. Time to first severe asthma exacerbation was measured from the date of randomization (that is, study treatment start date) to the onset date of first severe asthma exacerbation, or study treatment stop date for participants who completed the study without any severe asthma exacerbations (censored). Analyses of time to first severe asthma exacerbation was censored at Day 364. The number of participants with severe asthma exacerbation has been presented.

Time frame:
Up to Week 52
Reported as:
Number · Participants
Time to First Severe Asthma Exacerbation.
ParticipantsUsual CareFF/VI
Time to First Severe Asthma Exacerbation.654634
Statistical analysis
  • Usual Care vs FF/VI · Cox proportional hazards model · p = 0.504 (Cox proportional hazards model with randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age as covariates) · Hazard ratio (hr): 0.96 · 95% CI 0.86 to 1.07A hazard ratio \<1 indicated a lower risk with FF/VI compared with Usual Care
SecondaryMean Number of Salbutamol Inhalers Prescribed for Each Participant Over the 12 Month Treatment Period.

Salbutamol was prescribed as a rescue medication to be used as and when necessary throughout the study. The number of salbutamol inhalers used by each participant during the study was calculated based on the total number of inhalers (adjusted to an equivalence of 200 metered actuations) prescribed. Number of salbutamol inhalers prescribed during the study was derived taking the participants time on study medication into account so it corresponds to 12 months on treatment. The least square mean number of salbutamol inhalers prescribed per participant during the study has been presented. Only participants exposed to study drug for at least 30 days were included in the analysis.

Time frame:
Up to 12 months
Reported as:
Least squares mean · Mean number of inhalers per participant
Mean Number of Salbutamol Inhalers Prescribed for Each Participant Over the 12 Month Treatment Period.
Mean number of inhalers per participantUsual CareFF/VI
Mean Number of Salbutamol Inhalers Prescribed for Each Participant Over the 12 Month Treatment Period.8.0 ± 0.117.2 ± 0.11
Statistical analysis
  • Usual Care vs FF/VI · ANCOVA · p = <0.001 (ANCOVA adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender,age \& number of salbutamol inhalers in year prior to randomization) · Mean difference (final values): -0.8 · 95% CI -1.1 to -0.5Difference of FF/VI versus Usual Care has been presented.
SecondaryTime to Modification of Initial Therapy

Initial therapy is defined as the treatment that the participant was prescribed at randomization. Modification of initial therapy included any change in brand, dose or frequency of inhaler, that is, stepping up in class, dose or frequency, stepping down in class, dose or frequency, switching to another brand of inhaler, switching treatment arm or withdrawal from the study. Time to modification of initial therapy was measured from the date of randomization (that is, exposure start date) to the date of modification of initial therapy or date of treatment termination for participants who completed the study without modifiying initial therapy (censored). The number of participants with modification of initial therapy has been presented.

Time frame:
Up to Week 52
Reported as:
Number · Participants
Time to Modification of Initial Therapy
ParticipantsUsual CareFF/VI
Time to Modification of Initial Therapy488563
Statistical analysis
  • Usual Care vs FF/VI · Cox proportional hazards model · p = <0.001 (Cox proportional hazards model with randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age as covariates) · Hazard ratio (hr): 1.23 · 95% CI 1.09 to 1.38Hazard ratio for FF/VI versus Usual Care has been presented
SecondaryPercentage of Participants Who Have an Increase From Baseline of >=0.5 in Standardized Asthma Quality of Life Questionnaire [AQLQ(S)] Total Score at Week 52.

The AQLQ(S) contained 32 items under the following four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items) and environmental stimuli (4 items). The response format consisted of a seven-point scale where a value of 1 indicated "total impairment" and a value of 7 indicated "no impairment". The total AQLQ(S) score is the mean of all 32 items in the questionnaire and each individual domain score was calculated as the mean of the items within that domain. Hence, the total and domain scores were each defined on a range from 1 to 7 with higher scores indicating a higher quality of life. Baseline value is the value at Day 0 assessment. Change from Baseline is post dose visit value minus Baseline. The percentage of responders that is, participants with an increase from Baseline of \>=0.5 in AQLQ(S) total score has been presented. Only those participants available at the specified time point was analyzed.

Time frame:
Baseline (Day 0) and Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Have an Increase From Baseline of >=0.5 in Standardized Asthma Quality of Life Questionnaire [AQLQ(S)] Total Score at Week 52.
Percentage of participantsUsual CareFF/VI
Percentage of Participants Who Have an Increase From Baseline of >=0.5 in Standardized Asthma Quality of Life Questionnaire [AQLQ(S)] Total Score at Week 52.4355
Statistical analysis
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (Logistic regression adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender, age and Baseline score.) · Adjusted odds ratio: 1.79 · 95% CI 1.55 to 2.06Adjusted odds ratio of FF/VI with Usual Care has been presented.
SecondaryPercentage of Participants Who Have an Increase From Baseline of >=0.5 in AQLQ(S) Environmental Stimuli Domain Score at Week 52.

The AQLQ(S) contained 32 items under the following four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items) and environmental stimuli (4 items). The response format consisted of a seven-point scale where a value of 1 indicated "total impairment" and a value of 7 indicated "no impairment". The total environmental stimuli domain score was calculated as the mean of the items within the environmental stimuli domain. Hence, the environmental stimuli domain scores were each defined on a range from 1 to 7 with higher scores indicating a higher quality of life. Baseline value is the value at Day 0 assessment. Change from Baseline is post dose visit value minus Baseline. The percentage of responders that is, participants with an increase from Baseline of \>=0.5 in AQLQ(S) environmental stimuli domain score has been presented. Only those participants available at the specified time point was analyzed.

Time frame:
Baseline (Day 0) and Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Have an Increase From Baseline of >=0.5 in AQLQ(S) Environmental Stimuli Domain Score at Week 52.
Percentage of participantsUsual CareFF/VI
Percentage of Participants Who Have an Increase From Baseline of >=0.5 in AQLQ(S) Environmental Stimuli Domain Score at Week 52.5059
Statistical analysis
  • Usual Care vs FF/VI · Regression, Logistic · p = <0.001 (Logistic regression adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender, age and Baseline score.) · Adjusted odds ratio: 1.51 · 95% CI 1.31 to 1.73Adjusted odds ratio of FF/VI versus Usual Care has been presented.
SecondaryPercentage of Participants With Serious Adverse Event (SAE) of Pneumonia

A serious advent event (SAE) of pneumonia was defined as any SAE in the adverse event special interest (AESI) group of "pneumonia". The incidence of the SAEs of pneumonia for each treatment group is defined as the percentage of participants in that group who have experienced at least one SAE of pneumonia from start date of study treatment to the stop date of exposure + 28 days or date of study discontinuation, whichever is earliest. The percentage of participants with SAE of pneumonia has been presented.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Event (SAE) of Pneumonia
Percentage of participantsUsual CareFF/VI
Percentage of Participants With Serious Adverse Event (SAE) of Pneumonia11
Statistical analysis
  • Usual Care vs FF/VI · Incidence ratio: 1.4 · 95% CI 0.8 to 2.7Incidence ratio was calculated as percentage of participants who had at least one SAE of pneumonia in the FF/VI group divided by the percentage of participants who had at least one SAE of pneumonia in the Usual Care group.
SecondaryTime to First SAE of Pneumonia

An SAE of pneumonia was defined as any SAE in the AESI group of "pneumonia". The date of an event for an SAE of pneumonia was the AE onset date. Participants who do not have an SAE of pneumonia during the first 364 days of the treatment period (start date of exposure to min \[end date of exposure + 28 days, date of study discontinuation, start date of exposure + 363\]) were censored. Time to first SAE of pneumonia was measured from the date of randomization (that is, study treatment start date) to the onset date of first SAE of pneumonia. The number of participants with first on-treatment SAE of pneumonia has been presented.

Time frame:
Up to Week 52
Reported as:
Number · Participants
Time to First SAE of Pneumonia
ParticipantsUsual CareFF/VI
Time to First SAE of Pneumonia1623
Statistical analysis
  • Usual Care vs FF/VI · Cox proportional hazards model · p = 0.255 (Cox proportional hazards model with randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age as covariates.) · Hazard ratio (hr): 1.45 · 95% CI 0.77 to 2.74Hazard ratio for FF/VI versus Usual Care has been presented.
SecondaryNumber of Participants With Fatal SAEs of Pneumonia

All SAEs included in the AESI group of "pneumonia" were considered as an SAE of pneumonia. Fatal SAEs of pneumonia are SAEs that led to death of participants. The number of participants with fatal SAEs of pneumonia has been presented.

Time frame:
Up to Week 52
Reported as:
Number · Participants
Number of Participants With Fatal SAEs of Pneumonia
ParticipantsUsual CareFF/VI
Number of Participants With Fatal SAEs of Pneumonia31
SecondaryNumber of Participants With SAEs

An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events which may require medical or surgical intervention for example, invasive or malignant cancers; all events of possible drug-induced liver injury with hyperbilirubinemia. The number of participants with on-treatment SAEs has been summarized.

Time frame:
Up to Week 52
Reported as:
Number · Participants
Number of Participants With SAEs
ParticipantsUsual CareFF/VI
Number of Participants With SAEs284284
SecondaryNumber of Participants With Adverse Drug Reactions (ADRs)

An ADR is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, for which there is a reasonable possibility that the untoward occurrence is causally related to the medicinal product. ADRs are a subset of AEs for a given medicinal product.

Time frame:
Up to Week 52
Reported as:
Number · Participants
Number of Participants With Adverse Drug Reactions (ADRs)
ParticipantsUsual CareFF/VI
Number of Participants With Adverse Drug Reactions (ADRs)109326

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non- serious adverse drug reactions (ADRs) were collected from the start of study treatment and until the follow up contact (Up to Week 52).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Usual Care27/2,119 (1.3%)284/2,119 (13.4%)0/2,119 (0%)
FF/VI15/2,114 (0.7%)284/2,114 (13.4%)0/2,114 (0%)
Most frequent serious events
Showing 10 of 382
Most frequent serious events
EventUsual CareFF/VI
AsthmaRespiratory, thoracic and mediastinal disorders30/211924/2114
PneumoniaInfections and infestations13/211923/2114
Atrial fibrillationCardiac disorders14/21197/2114
Type 2 diabetes mellitusMetabolism and nutrition disorders13/211912/2114
Urinary tract infectionInfections and infestations4/211912/2114
Liver function test abnormalInvestigations7/211911/2114
CellulitisInfections and infestations11/21197/2114
Radius fractureInjury, poisoning and procedural complications9/21194/2114
Acute kidney injuryRenal and urinary disorders9/21196/2114
Ankle fractureInjury, poisoning and procedural complications2/21198/2114

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Usual CareFF/VITotal
Mean49.7 ± 16.6949.9 ± 16.0549.8 ± 16.37
Sex: Female, Male
Sex: Female, Male(Participants)Usual CareFF/VITotal
Female124112572498
Male8788571735
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Count of Participants)Usual CareFF/VITotal
African American/African Heritage254065
Asian - Central/South Asian Heritage354681
Asian - East Asian Heritage4913
Asian - Japanese Heritage202
Asian - South East Asian Heritage91827
Native Hawaiian or Other Pacific Islander112
White - Arabic/North African Heritage6511
White - White/Caucasian/European Heritage200219713973
Mixed race332356
Unknown213
08

Study locations

180 sites
  • GSK Investigational Site
    Altrincham, Cheshire WA14 2NW, United Kingdom
  • GSK Investigational Site
    Altrincham, Cheshire WA14 5ET, United Kingdom
  • GSK Investigational Site
    Altrincham, Cheshire WA14 5GR, United Kingdom
  • GSK Investigational Site
    Altrincham, Cheshire WA14 5NH, United Kingdom
  • GSK Investigational Site
    Altrincham, Cheshire WA14 5PF, United Kingdom
  • GSK Investigational Site
    Bowdon, Cheshire WA14 3BD, United Kingdom
  • GSK Investigational Site
    Cheadle Hulme, Cheshire SK8 5EG, United Kingdom
  • GSK Investigational Site
    Cheadle, Cheshire SK8 6LQ, United Kingdom
  • GSK Investigational Site
    Edgeley, Cheshire SK3 9LQ, United Kingdom
  • GSK Investigational Site
    Gatley, Cheshire SK84NG, United Kingdom
  • GSK Investigational Site
    Heald Green, Cheshire SK8 3QA, United Kingdom
  • GSK Investigational Site
    Sale, Cheshire M33 2RH, United Kingdom
  • GSK Investigational Site
    Sale, Cheshire M33 2UP, United Kingdom
  • GSK Investigational Site
    Sale, Cheshire M33 4BR, United Kingdom
  • GSK Investigational Site
    Sale, Cheshire M33 7SS, United Kingdom
  • GSK Investigational Site
    Stockport, Cheshire SK3 9NX, United Kingdom
  • GSK Investigational Site
    Timperley, Cheshire WA15 7DD, United Kingdom
  • GSK Investigational Site
    Timperley, Cheshire WA15 7UN, United Kingdom
  • GSK Investigational Site
    Altrincham, Greater Manchester WA14 2DW, United Kingdom
  • GSK Investigational Site
    Altrincham, Greater Manchester WA15 6PH, United Kingdom
  • GSK Investigational Site
    Broadway, Davyhulme, Greater Manchester M41 7WJ, United Kingdom
  • GSK Investigational Site
    Irlam, Manchester, Greater Manchester M44 5LH, United Kingdom
  • GSK Investigational Site
    Irlam, Greater Manchester M44 5LH, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M20 1EB, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M20 2DN, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M20 2RN, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M20 3BG, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M20 4SS, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M20 6WF, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M22 4DH, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M22 5DW, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M22 5RB, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M22 5RX, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M22 9UE, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M23 1JP, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M23 1JX, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M23 9AB, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M27 9LB, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M32 0DF, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M32 0PA, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M32 0RW, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 2TB, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 3HF, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 4WB, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 5JD, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 5PN, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 7SS, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M33 7XN, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 0NA, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 0SE, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 0TZ, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 5AA, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 7FN, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 7WJ, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester M41 8AA, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester WA15 6BP, United Kingdom
  • GSK Investigational Site
    Manchester, Greater Manchester WA15 7UN, United Kingdom
  • GSK Investigational Site
    Newall Green, Greater Manchester M23 2SY, United Kingdom
  • GSK Investigational Site
    Northenden, Greater Manchester M22 4DH, United Kingdom
  • GSK Investigational Site
    Northern Moor, Greater Manchester M23 0BX, United Kingdom
  • GSK Investigational Site
    Pendlebury, Greater Manchester M27 8HP, United Kingdom
  • GSK Investigational Site
    Salford, Manchester, Greater Manchester M6 6ES, United Kingdom
  • GSK Investigational Site
    Salford, Manchester, Greater Manchester M7 4TP, United Kingdom
  • GSK Investigational Site
    Salford, Greater Manchester M6 7HL, United Kingdom
  • GSK Investigational Site
    Salford, Greater Manchester M7 1RD, United Kingdom
  • GSK Investigational Site
    Stretford, Greater Manchester M32 9BD, United Kingdom
  • GSK Investigational Site
    Timperley, Greater Manchester WA15 6PH, United Kingdom
  • GSK Investigational Site
    Withington, Greater Manchester M20 1EY, United Kingdom
  • GSK Investigational Site
    Wythenshawe, Greater Manchester M22 0EP, United Kingdom
  • GSK Investigational Site
    Wythenshawe, Greater Manchester M22 5RN, United Kingdom
  • GSK Investigational Site
    Wythenshawe, Greater Manchester M22 5RX, United Kingdom
  • GSK Investigational Site
    Cadishead, Manchester, M44 5DD, United Kingdom
  • GSK Investigational Site
    Cheadle, SK8 5BB, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 0EA, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 0EJ, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 0LS, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 0NU, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 0PF, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 0TU, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 7JW, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 7NA, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 8AR, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 8JA, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 8QD, United Kingdom
  • GSK Investigational Site
    Eccles, Manchester, M30 9PS, United Kingdom
  • GSK Investigational Site
    Eccles, M30 0TU, United Kingdom
  • GSK Investigational Site
    Ellenbrook, Manchester, M28 1PB, United Kingdom
  • GSK Investigational Site
    Irlam, Manchester, M44 5LH, United Kingdom
  • GSK Investigational Site
    Irlam, Manchester, M44 6AJ, United Kingdom
  • GSK Investigational Site
    Irlam, Manchester, M44 6BL, United Kingdom
  • GSK Investigational Site
    Irlam, Manchester, M44 6FE, United Kingdom
  • GSK Investigational Site
    Irlam, Manchester, M44 6FN, United Kingdom
  • GSK Investigational Site
    Irlam, Salford, M44 6ZS, United Kingdom
  • GSK Investigational Site
    Little Hulton, Manchester, M28 0AY, United Kingdom
  • GSK Investigational Site
    Little Hulton, Manchester, M28 0BA, United Kingdom
  • GSK Investigational Site
    Little Hulton, Manchester, M38 9GR, United Kingdom
  • GSK Investigational Site
    Little Hulton, Manchester, M38 9LQ, United Kingdom
  • GSK Investigational Site
    Little Hulton, Manchester, M38 9RS, United Kingdom
  • GSK Investigational Site
    Little Hulton, Manchester, M38 9WX, United Kingdom
  • GSK Investigational Site
    Manchester, M16 0WL, United Kingdom

Showing the first 100 of 180 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Woodcock A, Janson C, Rees J, Frith L, Lofdahl M, Moore A, Hedberg M, Leather D. Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis. Thorax. 2022 Dec;77(12):1187-1192. doi: 10.1136/thoraxjnl-2021-218088. Epub 2022 Feb 7. PubMed 35131893 ↗
  • Kosinski M, Nelsen L, Rizio AA, Lay-Flurrie J, von Maltzahn R, Jacques L, Schatz M, Stanford RH, Svedsater H. Psychometric properties of the Asthma Control Test in 2 randomized clinical trials. J Allergy Clin Immunol Pract. 2021 Jan;9(1):561-563.e1. doi: 10.1016/j.jaip.2020.07.040. Epub 2020 Aug 6. No abstract available. PubMed 32771685 ↗
  • Svedsater H, Jones R, Bosanquet N, Jacques L, Lay-Flurrie J, Leather DA, Vestbo J, Collier S, Woodcock A. Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. Respir Med. 2018 Aug;141:198-206. doi: 10.1016/j.rmed.2018.06.003. Epub 2018 Jun 6. PubMed 30053967 ↗
  • Jacques L, Bakerly ND, New JP, Svedsater H, Lay-Flurrie J, Leather DA. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study. J Asthma. 2019 Jul;56(7):748-757. doi: 10.1080/02770903.2018.1490751. Epub 2018 Oct 16. PubMed 29972089 ↗
  • Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, Jones R, Collier S, Lay-Flurrie J, Frith L, Jacques L, Fletcher JL, Harvey C, Svedsater H, Leather D; Salford Lung Study Investigators. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017 Nov 18;390(10109):2247-2255. doi: 10.1016/S0140-6736(17)32397-8. Epub 2017 Sep 10. Erratum In: Lancet. 2017 Nov 18;390(10109):e40. doi: 10.1016/S0140-6736(17)32466-2. Lancet. 2018 Feb 3;391(10119):430. doi: 10.1016/S0140-6736(17)32553-9. PubMed 28903864 ↗
  • Woodcock A, Bakerly ND, New JP, Gibson JM, Wu W, Vestbo J, Leather D. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. BMC Pulm Med. 2015 Dec 10;15:160. doi: 10.1186/s12890-015-0150-8. PubMed 26651333 ↗
  • New JP, Bakerly ND, Leather D, Woodcock A. Obtaining real-world evidence: the Salford Lung Study. Thorax. 2014 Dec;69(12):1152-4. doi: 10.1136/thoraxjnl-2014-205259. Epub 2014 Mar 6. Erratum In: Thorax. 2015 Oct;70(10):1008. doi: 10.1136/thoraxjnl-2014-205259corr1. PubMed 24603195 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Dec 2016, 49 months.

Results were first posted in Jan 2019, 2 years 1 month after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 49 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2012
First posted
Oct 15, 2012
StartActual
Nov 1, 2012
Primary completionActual
Dec 1, 2016
CompletionActual
Dec 16, 2016
Results first posted
Jan 24, 2019
Last update
Jan 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01706198
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 15, 2012
Start date
Nov 1, 2012
Primary completion
Dec 1, 2016
Completion
Dec 16, 2016
Results posted
Jan 24, 2019
Last update
Jan 24, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion